

Drug Insight: antiangiogenic therapies for gastrointestinal cancers—focus on monoclonal antibodies

Anke Reinacher-Schick, Michael Pohl and Wolff Schmiegel

Nature Clinical Practice Gastroenterology & Hepatology (2008) **5**: 250–267 [doi:10.1038/ncpgasthep1097]

CORRIGENDUM

In the May 2008 issue, in the Review by Reinacher-Schick *et al.*, there was an error in the response rate figures reported for the study by Saltz *et al.*⁹⁵ in Table 2 on page 257. The correct response rates should be 38% versus 38% instead of 46.5% versus 37.5% as shown in the corrected Table 2 below. The Saltz *et al.* paper was available in abstract form only

at the time of publication, but has now been published in full; the updated reference details are included below.⁹⁵

Published online

12 August 2008

www.nature.com/clinicalpractice
doi:10.1038/ncpgasthep1237

Reference

- ⁹⁵ Saltz LB *et al.* (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: randomized phase III study. *J Clin Oncol* **26**: 2013–2019

Table 2 Examples of recent trials with the VEGF-specific antibody bevacizumab.

Study	Phase	N ^a	Protocol	Response rate (%)	P value	PFS (months)	P value	MS (months)	P value
CRC									
Hurwitz <i>et al.</i> (2004) ⁹⁰	III	411	IFL	35.0	<0.0001	6.2	<0.001	15.6	<0.001
		402	IFL + Bev	45.0	NA	10.6	NA	20.3	NA
Hochster <i>et al.</i> (2006) ⁹⁴	II	147	FOLFOX/bFOL/CapOx	22.0–43.0	NA	6.1–8.7	NA	18.2	NA
		213	FOLFOX/bFOL/CapOx + Bev	41.0–53.0	NA	8.3–10.3	NA	24.4	NA
Giantonio <i>et al.</i> (2007) ⁹⁹	III	289	FOLFOX; second-line	8.6	0.0001	4.7	0.0001	10.8	0.0011
		290	FOLFOX + Bev	22.7	NA	7.3	NA	13.0	NA
Saltz <i>et al.</i> (2007) ⁹⁵	III	701	FOLFOX/CapOx	38	0.99	8.0	0.002	19.9	0.077
		699	FOLFOX/CapOx + Bev	38	NA	9.4	NA	21.3	NA
Kabbinavar <i>et al.</i> (2005) ⁸⁹	III	105	5FU/LV	15.0	0.055	5.2	0.0002	12.9	0.16
		104	5FU/LV + Bev	26.0	NA	9.2	NA	16.6	NA
PaCa									
Kindler <i>et al.</i> (2007) ¹⁴²	III	300	Gem	11.3	NA	4.7	0.99	6.1	0.78
		302	Gem + Bev	13.1	NA	4.9	NA	5.8	NA
GC									
Shah <i>et al.</i> (2006) ¹³²	II	34	Cisplatin/CPT-11 + Bev	65.0	NA	8.3	NA	12.3	NA
HCC									
Schwartz <i>et al.</i> (2006) ¹²⁵	II	30	Bev	10.0	NA	6.5	NA	NA	NA
Sun <i>et al.</i> (2007) ¹²⁷	II	32	CapOx + Bev	13.3	NA	5.4	NA	10.6	NA
Thomas <i>et al.</i> (2007) ¹²⁸	II	29	Erlotinib + Bev	21.0	NA	9.0	NA	19.0	NA

^aNumber of patients per treatment arm. Abbreviations: 5FU, 5-fluorouracil; Bev, bevacizumab; bFOL, bevacizumab plus bolus 5FU/LV plus oxaliplatin; CapOx, capecitabine and oxaliplatin; CPT-11, irinotecan; CRC, colorectal cancer; FOLFOX, oxaliplatin, 5-fluorouracil and leucovorin; GC, gastric cancer; Gem, gemcitabine; HCC, hepatocellular cancer; IFL, bolus irinotecan plus 5-fluorouracil and leucovorin; LV, leucovorin; MS, median survival; NA, not available; PaCa, pancreatic cancer; PFS, progression-free survival; VEGF, vascular endothelial growth factor.